Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.


Related Content

MedImmune Pulling Ahead As AstraZeneca R&D Engine, Contributing Half Of Pipeline
Start-Up Quarterly Statistics, Q4 2013
AstraZeneca’s Soriot Outlines Epanova Approach, Reviews Tough First Year As CEO
Dunoyer Makes Leap To CFO As AZ’s BD Overhaul Continues
AZ’s Upbeat Pipeline Message Tarnished By Federal Probes, Poor Sales
Deals Of The Week: Academic Drug-Discovery Group’s Work Catching Industry’s Notice
MedImmune To Enhance Oncology Pipeline With Buyout Of Neighbor Amplimmune
Cancer Research UK’s CRT: A Bridge Between Big Pharma And Academia
Deals Of The Week: Janssen/CorImmun, AstraZeneca/Cellworks, Ferring/Albireo


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts